Please Wait.....
Report
North America Cold Sore Treatment (for HSV 1 Virus) Market
Market Report I 2024-05-01 I 179 Pages I Data Bridge Market Research
North America cold sore treatment (for HSV 1 virus) market is expected to reach USD 758.29 million by 2031, from USD 444.91 million in 2023 growing at the CAGR of 7.2% in the forecast period of 2024 to 2031.
Market Segmentation
North America Cold Sore Treatment (for HSV 1 Virus) Market, By Treatment Type (Medications, Applied Products, Cold Sore Patches, and Others(Non Medicated Products)), Route Of Administration (Oral, Topical, and Others), Mode Of Purchase (Over The Counter and Prescription Drug), Strain Type (Herpes Simplex Type 1 Virus and Herpes Simplex Type 2 Virus), Drug Type (Generic and Branded), Population Type (Adults, Pediatrics, and Geriatrics), Gender (Female and Male), End User (Home Healthcare, Hospitals, Specialty Clinics, and Others), Distribution Channel (Direct Tenders, Retail Sales, and Others), By Country (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2031
Overview of North America Cold Sore Treatment (for HSV 1 Virus) Market Dynamics
Drivers
- Growing prevalence of cold sore infection
- Growing awareness about cold sore symptoms and treatment options
- Impact of generic drugs on the global cold sore treatment (for HSV 1 virus) market
Restraints
- Development of drug-resistant strains of HSV-1 and H11 viruses
- Lack of curative treatment for infection
Opportunities
- Rising advancements in treatments for cold sore infections
- Increasing adoption of telemedicine and digital health solutions
Challenges
- Increasing complexity of vaccine development
Side effects associated with medications in treating cold sore
Market Players
The key market players for North America cold sore treatment (for HSV 1 virus) market are listed below:
- Fresenius SE & Co. KGaA
- Zydus Pharmaceuticals, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Quantum Health
- GSK plc.
- Haleon Group of Companies
- Church & Dwight Co., Inc.
- Hikma Pharmaceuticals PLC
- Viatris Inc.
- Carma Labs Inc.
- URGO MEDICAL
- Apotex Inc.
- Amneal Pharmaceuticals LLC
- Blistex Inc.
- FOCUS CONSUMER HEALTHCARE
- Hetero Healthcare Limited
- Amparo medical Technologies
- Devirex AG
1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 OVERVIEW OF THE NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET 19
1.4 CURRENCY AND PRICING 21
1.5 LIMITATIONS 21
1.6 MARKETS COVERED 21
2 MARKET SEGMENTATION 25
2.1 MARKETS COVERED 25
2.2 GEOGRAPHICAL SCOPE 26
2.3 YEARS CONSIDERED FOR THE STUDY 27
2.4 DBMR TRIPOD DATA VALIDATION MODEL 28
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 31
2.6 MULTIVARIATE MODELLING 32
2.7 MARKET APPLICATION COVERAGE GRID 33
2.8 PRODUCT LIFELINE CURVE 34
2.9 DBMR MARKET POSITION GRID 35
2.10 VENDOR SHARE ANALYSIS 36
2.11 SECONDARY SOURCES 37
2.12 ASSUMPTIONS 37
3 EXECUTIVE SUMMARY 38
4 PREMIUM INSIGHTS 41
4.1 PESTEL ANALYSIS 42
4.2 PORTER'S FIVE FORCES 43
5 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: REGULATIONS 44
5.1 REGULATION IN U.S.: 44
5.2 REGULATION IN CANADA: 45
5.3 REGULATION IN SPAIN: 45
5.4 REGULATION IN U.K.: 46
5.5 REGULATION IN INDIA 47
?
6 MARKET OVERVIEW 49
6.1 DRIVERS 51
6.1.1 GROWING PREVALENCE OF COLD SORE INFECTION 51
6.1.2 GROWING AWARENESS ABOUT COLD SORE SYMPTOMS AND TREATMENT OPTIONS 51
6.1.3 IMPACT OF GENERIC DRUGS ON THE NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET 52
6.2 RESTRAINTS 53
6.2.1 DEVELOPMENT OF DRUG-RESISTANT STRAINS OF HSV-1 AND H11 VIRUSES 53
6.2.2 LACK OF CURATIVE TREATMENT FOR INFECTION 54
6.3 OPPORTUNITIES 55
6.3.1 RISING ADVANCEMENTS IN TREATMENTS FOR COLD SORE INFECTIONS 55
6.3.2 INCREASING ADOPTION OF TELEMEDICINE AND DIGITAL HEALTH SOLUTIONS 56
6.4 CHALLENGES 57
6.4.1 INCREASING COMPLEXITY OF VACCINE DEVELOPMENT 57
6.4.2 SIDE EFFECTS ASSOCIATED WITH MEDICATIONS IN TREATING COLD SORE 58
7 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE 59
7.1 OVERVIEW 60
7.2 MEDICATIONS 63
7.2.1 ANTIVIRAL AGENTS 63
7.2.2 ANALGESIC AGENTS 64
7.2.3 OTHERS 64
7.3 APPLIED PRODUCTS 64
7.3.1 BRANDED 65
7.3.2 GENERICS 65
7.4 COLD SORE PATCHES 66
7.4.1 SEMI OCCLUSIVE HYDROCOLLOID PATCH 66
7.4.2 FILM FORMING PATCH 66
7.5 OTHERS (NON MEDICATED PRODUCTS) 67
8 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION 68
8.1 OVERVIEW 69
8.2 ORAL 72
8.2.1 TABLETS 72
8.2.2 CAPSULES 72
8.2.3 OTHERS 72
?
8.3 TOPICAL 73
8.3.1 CREAM 73
8.3.2 LIP BALM 73
8.3.3 OTHERS 73
8.4 OTHERS 74
9 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE 75
9.1 OVERVIEW 76
9.2 OVER THE COUNTER 79
9.3 PRESCRIPTION DRUG 79
10 NORTH AMERICA COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY STRAIN TYPE 80
10.1 OVERVIEW 81
10.2 HERPES SIMPLEX TYPE 1 VIRUS 84
10.3 HERPES SIMPLEX TYPE 2 VIRUS 84
11 NORTH AMERICA COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY DRUG TYPE 85
11.1 OVERVIEW 86
11.2 GENERIC 89
11.3 BRANDED 89
12 NORTH AMERICA COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY POPULATION TYPE 91
12.1 OVERVIEW 92
12.2 ADULTS 95
12.3 PEDIATRICS 95
12.4 GERIATRICS 96
13 NORTH AMERICA COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY GENDER 97
13.1 OVERVIEW 98
13.2 FEMALE 101
13.3 MALE 101
?
14 NORTH AMERICA COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY END USER 102
14.1 OVERVIEW 103
14.2 HOME HEALTHCARE 106
14.3 HOSPITALS 106
14.4 SPECIALTY CLINICS 107
14.5 OTHERS 107
15 NORTH AMERICA COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL 108
15.1 OVERVIEW 109
15.2 DIRECT TENDERS 112
15.3 RETAIL SALES 112
16 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION 114
16.1 NORTH AMERICA 117
16.1.1 U.S. 123
16.1.2 CANADA 129
16.1.3 MEXICO 135
17 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY LANDSCAPE 141
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS 142
19 COMPANY PROFILE 143
19.1 FRESENIUS SE & CO. KGAA 143
19.1.1 COMPANY SNAPSHOT 143
19.1.2 REVENUE ANALYSIS 143
19.1.3 COMPANY SHARE ANALYSIS 144
19.1.4 PRODUCT PORTFOLIO 144
19.1.5 RECENT DEVELOPMENT 144
19.2 ZYDUS PHARMACEUTICALS INC. 145
19.2.1 COMPANY SNAPSHOT 145
19.2.2 COMPANY SHARE ANALYSIS 145
19.2.3 PRODUCT PORTFOLIO 146
19.2.4 RECENT DEVELOPMENT 146
?
19.3 TEVA PHARMACEUTICAL INDUSTRIES LTD. 147
19.3.1 COMPANY SNAPSHOT 147
19.3.2 REVENUE ANALYSIS 147
19.3.3 COMPANY SHARE ANALYSIS 148
19.3.4 PRODUCT PORTFOLIO 148
19.3.5 RECENT DEVELOPMENT 149
19.4 NOVARTIS AG 150
19.4.1 COMPANY SNAPSHOT 150
19.4.2 REVENUE ANALYSIS 150
19.4.3 COMPANY SHARE ANALYSIS 151
19.4.4 PRODUCT PORTFOLIO 151
19.4.5 RECENT DEVELOPMENT 151
19.5 SUN PHARMACEUTICALS INDUSTRIES LIMITED 152
19.5.1 COMPANY SNAPSHOT 152
19.5.2 REVENUE ANALYSIS 152
19.5.3 COMPANY SHARE ANALYSIS 153
19.5.4 PRODUCT PORTFOLIO 153
19.5.5 RECENT DEVELOPMENT 153
19.6 AMNEAL PHARMACEUTICALS LLC 154
19.6.1 COMPANY SNAPSHOT 154
19.6.2 REVENUE ANALYSIS 154
19.6.3 PRODUCT PORTFOLIO 155
19.6.4 RECENT DEVELOPMENT 155
19.7 AMPARO MEDICAL TECHNOLOGIES 156
19.7.1 COMPANY SNAPSHOT 156
19.7.2 PRODUCT PORTFOLIO 156
19.7.3 RECENT DEVELOPMENT 156
19.8 APOTEX INC. 157
19.8.1 COMPANY SNAPSHOT 157
19.8.2 PRODUCT PORTFOLIO 157
19.8.3 RECENT DEVELOPMENT 157
19.9 BLISTEX INC. 158
19.9.1 COMPANY SNAPSHOT 158
19.9.2 PRODUCT PORTFOLIO 158
19.9.3 RECENT DEVELOPMENT 158
19.10 CARMA LABS INC. 159
19.10.1 COMPANY SNAPSHOT 159
19.10.2 PRODUCT PORTFOLIO 159
19.10.3 RECENT DEVELOPMENT 159
?
19.11 CHURCH & DWIGHT CO., INC. 160
19.11.1 COMPANY SNAPSHOT 160
19.11.2 REVENUE ANALYSIS 160
19.11.3 PRODUCT PORTFOLIO 161
19.11.4 RECENT DEVELOPMENT 161
19.12 DEVIREX AG 162
19.12.1 COMPANY SNAPSHOT 162
19.12.2 PRODUCT PORTFOLIO 162
19.12.3 RECENT DEVELOPMENT 162
19.13 FOCUS CONSUMER HEALTHCARE 163
19.13.1 COMPANY SNAPSHOT 163
19.13.2 PRODUCT PORTFOLIO 163
19.13.3 RECENT DEVELOPMENT 163
19.14 GSK PLC. 164
19.14.1 COMPANY SNAPSHOT 164
19.14.2 REVENUE ANALYSIS 164
19.14.3 PRODUCT PORTFOLIO 165
19.14.4 RECENT DEVELOPMENT 165
19.15 HALEON GROUP OF COMPANIES 166
19.15.1 COMPANY SNAPSHOT 166
19.15.2 REVENUE ANALYSIS 166
19.15.3 PRODUCT PORTFOLIO 167
19.15.4 RECENT DEVELOPMENT 167
19.16 HETERO HEALTH CARE LIMITED 168
19.16.1 COMPANY SNAPSHOT 168
19.16.2 PRODUCT PORTFOLIO 168
19.16.3 RECENT DEVELOPMENT 168
19.17 HIKMA PHARMACEUTICALS PLC 169
19.17.1 COMPANY SNAPSHOT 169
19.17.2 REVENUE ANALYSIS 169
19.17.3 PRODUCT PORTFOLIO 170
19.17.4 RECENT DEVELOPMENT 170
19.18 QUANTUM HEALTH 171
19.18.1 COMPANY SNAPSHOT 171
19.18.2 PRODUCT PORTFOLIO 171
19.18.3 RECENT DEVELOPMENT 172
19.19 URGO MEDICAL 173
19.19.1 COMPANY SNAPSHOT 173
19.19.2 PRODUCT PORTFOLIO 173
19.19.3 RECENT DEVELOPMENT 173
19.20 VIATRIS INC. 174
19.20.1 COMPANY SNAPSHOT 174
19.20.2 REVENUE ANALYSIS 174
19.20.3 PRODUCT PORTFOLIO 175
19.20.4 RECENT DEVELOPMENT 175
20 QUESTIONNAIRE 176
21 RELATED REPORTS 179
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security